Harbarth S, Rutschmann O, Sudre P, Pittet D
Department of Internal Medicine, University Hospital of Geneva, Switzerland.
Arch Intern Med. 1998 Jan 26;158(2):182-9. doi: 10.1001/archinte.158.2.182.
Uncertainties remain about the contribution of methicillin resistance to morbidity and mortality associated with bacteremia caused by Staphylococcus aureus.
To assess the impact of methicillin resistance on patient outcome after staphylococcal bacteremia.
We investigated a cohort of 145 patients with methicillin-sensitive S aureus bloodstream infection (MSSA BSI) and 39 patients with methicillin-resistant S aureus bloodstream infection (MRSA BSI) and further performed a pairwise-matched (1:1) case-control study. All patients in the University Hospital of Geneva, Geneva, Switzerland, with clinically significant staphylococcal bacteremia between January 1, 1994, and December 31, 1995, were included in the study. For the case-control study, cases were defined as patients with MRSA BSI; control patients with MSSA BSI were selected in a stepwise manner according to the following matching variables: age, sex, number of comorbidities, severity of underlying illness, and prior length of stay in the hospital. Matching was successful for 97% of the cohort.
The in-hospital mortality after staphylococcal bacteremia.
In the population-based study, the relative hazard of death among patients with MRSA BSI (n = 39, 14 deaths, 36% fatality rate) compared with patients with MSSA BSI (n = 145, 40 deaths, 28% fatality rate) was 1.1 (95% confidence interval, 0.5-2.1), after adjusting for age and length of stay from admission to the onset of bloodstream infection. Following pairwise matching (n = 38), the in-hospital mortality was 34% in both groups (odds ratio, 1.0; 95% confidence interval, 0.4-2.5). Infection was the probable or definite cause of death in 54% of patients with MRSA BSI and 69% of patients with MSSA BSI who died.
Methicillin resistance in patients with S aureus bacteremia had no significant impact on patient outcome as measured by in-hospital mortality after adjustment was made for major confounders.
耐甲氧西林对金黄色葡萄球菌所致菌血症相关的发病和死亡的影响仍不明确。
评估耐甲氧西林对葡萄球菌菌血症患者预后的影响。
我们调查了145例甲氧西林敏感金黄色葡萄球菌血流感染(MSSA BSI)患者和39例耐甲氧西林金黄色葡萄球菌血流感染(MRSA BSI)患者的队列,并进一步进行了配对(1:1)病例对照研究。瑞士日内瓦大学医院1994年1月1日至1995年12月31日期间所有患有具有临床意义的葡萄球菌菌血症的患者均纳入研究。在病例对照研究中,病例定义为MRSA BSI患者;根据以下匹配变量逐步选择MSSA BSI对照患者:年龄、性别、合并症数量、基础疾病严重程度以及既往住院时间。97%的队列匹配成功。
葡萄球菌菌血症后的院内死亡率。
在基于人群的研究中,调整年龄和从入院到血流感染发作的住院时间后,与MSSA BSI患者(n = 145,40例死亡,病死率28%)相比,MRSA BSI患者(n = 39,14例死亡,病死率36%)的相对死亡风险为1.1(95%置信区间,0.5 - 2.1)。配对后(n = 38),两组的院内死亡率均为34%(比值比,1.0;95%置信区间,0.4 - 2.5)。在死亡的MRSA BSI患者中,54%以及MSSA BSI患者中69%的感染是可能或确定的死亡原因。
在对主要混杂因素进行调整后,以院内死亡率衡量,金黄色葡萄球菌菌血症患者的耐甲氧西林对患者预后无显著影响。